Vividion Therapeutics Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
270
- Latest Deal Type
-
IPO
- (Cancelled)
- Latest Deal Amount
-
$100M
Vividion Therapeutics General Information
Description
Developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses. The company's platform applies chemical proteomics to expand the druggable proteome and addresses difficult targets providing transformative treatments, enabling healthcare professionals to eliminate artifacts and create proteome-wide drug interaction maps, for simultaneous target engagement and global selectivity profiling.
Contact Information
Website
www.vividion.com(Operating Subsidiary)
Corporate Office
- 5820 Nancy Ridge Drive
- San Diego, CA 92121
- United States
Corporate Office
- 5820 Nancy Ridge Drive
- San Diego, CA 92121
- United States
Vividion Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. IPO | 20-Aug-2021 | $100M | Cancelled | Generating Revenue | ||
| 7. Merger/Acquisition | 01-Aug-2021 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series C) | 01-Feb-2021 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series B) | 30-Apr-2019 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 05-Mar-2018 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A3) | 24-Oct-2017 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A2) | 02-Feb-2017 | $50M | $53.5M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 11-Apr-2016 | $3.5M | $3.5M | Completed | Generating Revenue |
Vividion Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 67,333,334 | $0.001000 | 6% | $0.6 | $0.6 | 1x | $0.6 | 24.17% |
| Series A | 18,118,465 | $0.001000 | 6% | $0.25 | $0.25 | 1x | $0.25 | 6.5% |
Vividion Therapeutics Comparisons
Industry
Financing
Details
Vividion Therapeutics Competitors (130)
One of Vividion Therapeutics’s 130 competitors is Enveda, a Venture Capital-Backed company based in Boulder, CO.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Enveda | Venture Capital-Backed | Boulder, CO | ||||
| TriGemX Bio | Venture Capital-Backed | New York, NY | ||||
| Abcuro | Venture Capital-Backed | Newton, MA | ||||
| InterAx | Venture Capital-Backed | Schlieren, Switzerland | ||||
| Exo Therapeutics | Venture Capital-Backed | Cambridge, MA |
Vividion Therapeutics Patents
Vividion Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026206950-A1 | (s,e)-n-(1-cyclopropyl-3-(methylsulfonyl)allyl)-2-(1,1-difluoroethyl)-4-phenoxypyrimidine-5-carboxamide for treating cancer | Pending | 24-Mar-2025 | ||
| WO-2026206763-A1 | Compounds and methods for modulating ras-pi3k | Pending | 24-Mar-2025 | ||
| WO-2026128789-A1 | Keap1 inhibitors and uses thereof | Pending | 13-Dec-2024 | ||
| WO-2026128791-A1 | Keap1 inhibitors and uses thereof | Pending | 13-Dec-2024 | ||
| US-20250228866-A1 | Crystalline form of (r)-1-(3-(3-(4-aminopyrimidin-2-yl)-5-chlorophenyl)morpholino)prop-2-en-1-one | Pending | 10-Jun-2024 | A61K31/5377 |
Vividion Therapeutics Signals
Vividion Therapeutics Former Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARCH Venture Partners | Venture Capital | Minority | ||
| Acuta Capital Partners | Hedge Fund | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Altitude Life Science Ventures | Venture Capital | Minority | ||
| Avoro Capital | Venture Capital | Minority |
Vividion Therapeutics Investments & Acquisitions (2)
Vividion Therapeutics’s most recent deal was a Corporate Asset Purchase with Roche (Werner Helicase Inhibitor Rights). The deal was made on 04-Jun-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Roche (Werner Helicase Inhibitor Rights) | 04-Jun-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Tavros Therapeutics | 23-Dec-2024 | Merger/Acquisition | Drug Discovery |
Vividion Therapeutics FAQs
-
When was Vividion Therapeutics founded?
Vividion Therapeutics was founded in 2013.
-
Where is Vividion Therapeutics headquartered?
Vividion Therapeutics is headquartered in San Diego, CA.
-
What is the size of Vividion Therapeutics?
Vividion Therapeutics has 270 total employees.
-
What industry is Vividion Therapeutics in?
Vividion Therapeutics’s primary industry is Drug Discovery.
-
Is Vividion Therapeutics a private or public company?
Vividion Therapeutics is a Private company.
-
What is Vividion Therapeutics’s current revenue?
The current revenue for Vividion Therapeutics is .
-
How much funding has Vividion Therapeutics raised over time?
Vividion Therapeutics has raised $379M.
-
Who are Vividion Therapeutics’s investors?
ARCH Venture Partners, Acuta Capital Partners, Alexandria Venture Investments, Altitude Life Science Ventures, and Avoro Capital are 5 of 23 investors who have invested in Vividion Therapeutics.
-
Who are Vividion Therapeutics’s competitors?
Enveda, TriGemX Bio, Abcuro, InterAx, and Exo Therapeutics are some of the 130 competitors of Vividion Therapeutics.
-
When was Vividion Therapeutics acquired?
Vividion Therapeutics was acquired on 20-Aug-2021.
-
Who acquired Vividion Therapeutics?
Vividion Therapeutics was acquired by Bayer.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process